Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M20,182Revenue (TTM) $M1,661Net Margin (%)-13.2Altman Z-Score5.7
Enterprise Value $M19,794EPS (TTM) $-0.9Operating Margin %-5.0Piotroski F-Score5
P/E(ttm)--Beneish M-Score-2.4Pre-tax Margin (%)-9.9Higher ROA y-yY
Price/Book19.510-y EBITDA Growth Rate %--Quick Ratio2.0Cash flow > EarningsY
Price/Sales11.85-y EBITDA Growth Rate %--Current Ratio2.1Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-8.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-22.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M248ROIC % (ttm)-9.1Gross Margin Increase y-yN

Gurus Latest Trades with VRTX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
VRTXJoel Greenblatt 2016-09-30 Reduce-0.04%$85 - $102.83
($94.5)
$ 81.37-14%Reduce -38.60%66,716
VRTXGeorge Soros 2016-09-30 Sold Out -0.02%$85 - $102.83
($94.5)
$ 81.37-14%Sold Out0
VRTXKen Fisher 2016-09-30 Add$85 - $102.83
($94.5)
$ 81.37-14%Add 1.10%5,168
VRTXJoel Greenblatt 2016-06-30 Add0.1%$79.15 - $96.09
($86.3)
$ 81.37-6%Add 2053.31%108,656
VRTXLeucadia National 2016-06-30 Sold Out -0.04%$79.15 - $96.09
($86.3)
$ 81.37-6%Sold Out0
VRTXVanguard Health Care Fund 2016-06-30 Add0.04%$79.15 - $96.09
($86.36)
$ 81.37-6%Add 1.95%12,914,741
VRTXJohn Paulson 2016-06-30 Sold Out -0.04%$79.15 - $96.09
($86.3)
$ 81.37-6%Sold Out0
VRTXGeorge Soros 2016-06-30 Buy 0.02%$79.15 - $96.09
($86.3)
$ 81.37-6%New holding6,300
VRTXKen Fisher 2016-06-30 Reduce$79.15 - $96.09
($86.3)
$ 81.37-6%Reduce -0.83%5,112
VRTXVanguard Health Care Fund 2016-03-31 Add0.5%$78.4 - $125.83
($91.01)
$ 81.37-11%Add 28.91%12,668,241
VRTXLeucadia National 2016-03-31 Buy 0.04%$78.4 - $125.83
($91.01)
$ 81.37-11%New holding3,300
VRTXJohn Paulson 2016-03-31 Add0.01%$78.4 - $125.83
($91.01)
$ 81.37-11%Add 32.54%61,500
VRTXJoel Greenblatt 2016-03-31 Reduce-0.01%$78.4 - $125.83
($91.01)
$ 81.37-11%Reduce -57.21%5,046
VRTXKen Fisher 2016-03-31 Reduce$78.4 - $125.83
($91.01)
$ 81.37-11%Reduce -7.00%5,155
VRTXVanguard Health Care Fund 2015-12-31 Add0.1%$109.03 - $133.26
($121.16)
$ 81.37-33%Add 4.34%9,827,411
VRTXJohn Paulson 2015-12-31 Buy 0.04%$109.03 - $133.26
($121.16)
$ 81.37-33%New holding46,400
VRTXJoel Greenblatt 2015-12-31 Buy 0.02%$109.03 - $133.26
($121.16)
$ 81.37-33%New holding11,793
VRTXKen Fisher 2015-12-31 Add$109.03 - $133.26
($120.93)
$ 81.37-33%Add 12.48%5,543
VRTXVanguard Health Care Fund 2015-09-30 Reduce-0.03%$98.5 - $141.48
($128.47)
$ 81.37-37%Reduce -1.21%9,418,411
VRTXKen Fisher 2015-09-30 Add$98.5 - $141.48
($128.47)
$ 81.37-37%Add 12.56%4,928
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

VRTX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


VRTX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
BOGER JOSHUA SDirector 2017-01-11Sell8,000$82.48-1.9view
BOGER JOSHUA SDirector 2017-01-04Sell6,500$77.134.9view
BOGER JOSHUA SDirector 2016-12-29Sell6,500$74.338.85view
BOGER JOSHUA SDirector 2016-12-21Sell6,500$74.169.1view
BOGER JOSHUA SDirector 2016-12-14Sell6,500$77.524.37view
BOGER JOSHUA SDirector 2016-12-07Sell6,500$75.157.66view
BOGER JOSHUA SDirector 2016-11-30Sell6,500$83.48-3.08view
BOGER JOSHUA SDirector 2016-11-23Sell6,500$86.47-6.43view
BOGER JOSHUA SDirector 2016-11-16Sell6,500$91.55-11.62view
Sachdev AmitEVP, Policy, Access & Value 2016-11-15Sell116$93.36-13.34view

Quarterly/Annual Reports about VRTX:

    News about VRTX:

    Articles On GuruFocus.com
    Galapagos NV Announces Results From Cystic Fibrosis Treatment Study Dec 27 2016 
    Piotroski F-Score in the Real World Dec 19 2016 
    Testing of Treatment for Cystic Fibrosis Patients Begins Nov 29 2016 
    Edward Owens Top 2nd Quarter Investments Aug 03 2016 
    Vanguard Health Care Fund Ups Stake in High-Conviction Stocks May 10 2016 
    Vanguard Boosts Stake in Incyte in 1st Quarter May 02 2016 
    Kyle Bass Sells Stakes in 11 Health Care Companies Mar 01 2016 
    Lee Ainslie Adds 90 New Stocks to His Portfolio Within the First Quarter May 20 2015 
    Analysts Confident That Vertex Pharmaceuticals' CF Drug Will Receive FDA Approval May 13 2015 
    Fate Of Cystic Fibrosis Drug By Vertex Is Now Dependent On FDA Approval May 13 2015 

    More From Other Websites
    Seaport traffic gets dose of relief as Vertex joins shuttle program Jan 19 2017
    Baird Has 4 Red-Hot Biotechs to Buy for 2017 With Huge Upside Potential Jan 19 2017
    Vertex Pharma (VRTX) Q4 Earnings: Stock Likely to Beat? Jan 19 2017
    Blog Coverage Paratek Announced Enrollment Completion in Omadacycline Phase-3 Community-Acquired... Jan 19 2017
    Gilead 2017 Outlook Hamstrung On Hep C, But RBC Bullish On Amgen, Biogen Jan 18 2017
    Concert Offers Update on Cystic Fibrosis Drug, Stock Down Jan 18 2017
    Why Vertex Pharmaceuticals (VRTX) Could Be Positioned for a Surge Jan 18 2017
    Merck KGaA, Vertex Announce Tie-Up for Oncology Programs Jan 12 2017
    Vertex Pharmaceuticals, Inc. – Value Analysis (NASDAQ:VRTX) : January 11, 2017 Jan 11 2017
    Vertex deals cancer drug programs to Merck KGaA for $230M Jan 11 2017
    VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Entry into a Material Definitive Agreement Jan 11 2017
    Merck KGaA, Darmstadt, Germany Licenses Four Oncology Research and Development Programs from Vertex Jan 11 2017
    Merck KGaA, Darmstadt, Germany Licenses Four Oncology Research and Development Programs from Vertex Jan 11 2017
    Jefferies Has 5 Top Biotech Stocks to Buy for 2017 Jan 10 2017
    Vertex Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VRTX-US :... Jan 10 2017
    Vertex Sales Guidance For Cystic Fibrosis Drug Orkambi Misses Jan 09 2017
    Vertex Pharmaceuticals to Rely on Acquisitions to Diversify Its Business Jan 09 2017
    Vertex Pharma Will Use Deals to Diversify Beyond Cystic Fibrosis Jan 09 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)